Fikry Heba, Saleh Lobna A, Mohammed Osama A, Doghish Ahmed S, Elsakka Elsayed G E, Hashish Abdullah A, Alfaifi Jaber, Alamri Mohannad Mohammad S, Adam Masoud I E, Atti Mohammed A, Mahmoud Faten A, Alkhalek Hadwa Ali Abd
Department of Histology and Cell Biology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Department of Clinical Pharmacology. Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt; Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia.
Life Sci. 2024 Dec 15;359:123220. doi: 10.1016/j.lfs.2024.123220. Epub 2024 Nov 5.
Diabetic patients commonly experience hyposalivation, which can cause challenges with eating, swallowing, dry mouth, and speaking. It also raises the likelihood of developing periodontal disease. This study aimed to evaluate if agmatine could improve the rate of salivation in rats with hyposalivation induced by streptozotocin (STZ). Five groups of Wistar rats were utilized with 10 animals in each group. They were classified as follows; Negative control group (G1), agmatine (G2) group, and Nicotinamide (NA)-STZ (G3) group; received a single intraperitoneal dose of 65 mg/kg of STZ after NA injection. NA was administered to protect residual β cells and enhance their insulin secretion; NA-STZ + Metformin (G4) Metformin-treated diabetic group; at day 10 diabetic rats received 50mg/kg orally for 28 days, and NA-STZ + Agmatine (G5) at day 10 diabetic rats received a daily intraperitoneal dose of 300 mg/kg Agmatine for 28 days. The salivary flow rate was assessed weekly. Then, the animals were euthanized, both parotid (PG) and submandibular (SMG) salivary glands were dissected, and the following parameters were assessed; salivary glands' histopathology, aquaporin 5 (AQP5), caspase-3, E-cadherin expressions, inflammatory markers and finally, salivary glands' oxidative stress status. Agmatine has alleviated the salivary glands' dysfunction in STZ-induced diabetic rats. It normalized diabetes mellitus-associated salivary glands' abnormalities including histopathological abnormalities, decreased AQP5 and E-cadherin expressions, increased caspase-3 expression, and oxidative stress and inflammatory parameters. Agmatine alleviates diabetes mellitus-associated hyposalivation. It can promote PGs and SMGs function through its histological and AQP5 expression improvements.
糖尿病患者常出现唾液分泌减少，这会给进食、吞咽、口干和说话带来困难。这也增加了患牙周病的可能性。本研究旨在评估胍丁胺是否能提高链脲佐菌素（STZ）诱导的唾液分泌减少大鼠的唾液分泌率。使用了五组Wistar大鼠，每组10只动物。它们被分类如下：阴性对照组（G1）、胍丁胺（G2）组和烟酰胺（NA）-STZ（G3）组；在注射NA后腹腔注射单次剂量65mg/kg的STZ。给予NA以保护残余β细胞并增强其胰岛素分泌；NA-STZ + 二甲双胍（G4）二甲双胍治疗的糖尿病组；在第10天，糖尿病大鼠口服50mg/kg，持续28天，以及NA-STZ + 胍丁胺（G5）在第10天，糖尿病大鼠腹腔注射每日剂量300mg/kg的胍丁胺，持续28天。每周评估唾液流速。然后，对动物实施安乐死，解剖腮腺（PG）和下颌下腺（SMG），并评估以下参数；唾液腺的组织病理学、水通道蛋白5（AQP5）、半胱天冬酶-3、E-钙黏蛋白表达、炎症标志物，最后是唾液腺的氧化应激状态。胍丁胺减轻了STZ诱导的糖尿病大鼠唾液腺的功能障碍。它使与糖尿病相关的唾液腺异常正常化，包括组织病理学异常、AQP5和E-钙黏蛋白表达降低、半胱天冬酶-3表达增加以及氧化应激和炎症参数。胍丁胺减轻与糖尿病相关的唾液分泌减少。它可以通过改善组织学和AQP5表达来促进腮腺和下颌下腺的功能。
